Shilpa Medicare Limited has informed the Exchange about Shilpa Pharma Inc, a wholly owned subsidiary of the Company has agreed to make a strategic investment in the form of SAFE (Simple Agreement for Future Equity) Notes in Alveolus Bio, a biotech startup based out of USA
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shilpa Pharma Inc, a wholly owned subsidiary of Shilpa Medicare, will invest US$ 2 million in Alveolus Bio, a US-based biotech startup working on inhaled therapies for chronic lung diseases like COPD, Pulmonary Fibrosis, and Asthma. The investment is structured as SAFE (Simple Agreement for Future Equity) Notes, which will convert into equity shares later based on future valuation milestones. Alveolus Bio reported revenue of about US$ 1.19 million in 2024 (up from US$ 0.43 million in 2023) and has a paid-up capital of US$ 1.5 million. Additionally, Shilpa Biologics Private Limited, another wholly owned subsidiary and the biologics arm of Shilpa Medicare, will serve as the exclusive global development and manufacturing partner for Alveolus Bio. The investment is expected to be completed within one month and is not a related party transaction.
This is a relatively small investment (~$2M) but strategically significant as it expands Shilpa Medicare's biologics footprint into cutting-edge US biotech and secures exclusive CDMO (contract development & manufacturing) rights through its biologics subsidiary. For shareholders, this signals management's push into innovative respiratory therapies and global biotech partnerships, though the financial impact on near-term earnings is minimal given the modest cheque size.